What is the recommended treatment for acute nephrotic syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Acute Nephrotic Syndrome

For children with acute nephrotic syndrome, initiate oral glucocorticoids (prednisone or prednisolone) for either 8 weeks (4 weeks daily followed by 4 weeks alternate-day) or 12 weeks (6 weeks daily followed by 6 weeks alternate-day), combined with supportive measures including sodium restriction, loop diuretics, and ACE inhibitors or ARBs. 1

Initial Treatment Approach

The cornerstone of acute nephrotic syndrome treatment is oral glucocorticoid therapy, as recommended by the most recent KDIGO 2025 guidelines 1. This represents the highest quality evidence available and should guide your initial management strategy.

Glucocorticoid Regimen

You have two evidence-based options for initial treatment:

  • 8-week regimen: 4 weeks of daily glucocorticoids followed by 4 weeks of alternate-day dosing
  • 12-week regimen: 6 weeks of daily glucocorticoids followed by 6 weeks of alternate-day dosing

Both regimens carry a 1B recommendation strength, meaning you can choose either based on individual patient factors such as age, weight, and risk of glucocorticoid toxicity 1.

Essential Supportive Measures

While glucocorticoids address the underlying pathophysiology, supportive therapy is critical for managing complications and improving quality of life:

Fluid and Electrolyte Management:

  • Sodium restriction (typically 1-2 g/day)
  • Fluid restriction if significant edema present
  • Loop diuretics (furosemide) for volume overload 2, 3

Antiproteinuric Therapy:

  • ACE inhibitors or ARBs to reduce proteinuria and provide renoprotection 2, 3

Lipid Management:

  • Statins to normalize serum lipid concentrations, particularly important given the hyperlipidemia associated with nephrotic syndrome 2

Important Clinical Considerations

Complications to Monitor

Patients with acute nephrotic syndrome face several serious complications that require vigilant monitoring:

  • Thromboembolism: Deep vein thrombosis, renal vein thrombosis, and pulmonary emboli are significant risks 2, 3
  • Infections: Increased susceptibility due to immunoglobulin loss and immunosuppression 3, 4
  • Acute kidney injury: Can occur from the underlying disease process 3

When to Escalate Treatment

If the patient develops steroid-resistant nephrotic syndrome (failure to achieve remission after 4-6 weeks of glucocorticoid therapy), second-line therapy with cyclosporine or tacrolimus is recommended 1. This represents a critical decision point that significantly impacts long-term outcomes.

For frequently relapsing or steroid-dependent cases, glucocorticoid-sparing agents should be introduced to prevent relapses and minimize toxicity. The KDIGO 2025 guidelines no longer distinguish between first-line and alternative agents, but suggest:

  • Frequently relapsing NS: Oral cyclophosphamide or levamisole may be preferable
  • Steroid-dependent NS: Mycophenolate mofetil, rituximab, calcineurin inhibitors, or cyclophosphamide 1

Critical Pitfall to Avoid

Do not routinely give daily glucocorticoids during upper respiratory tract infections in children with frequently relapsing or steroid-dependent nephrotic syndrome, as recent evidence (PREDNOS2 study) shows no benefit in preventing infection-associated relapses 1. This represents an important update from previous practice patterns.

Special Populations

Adults vs. Children

While the evidence provided focuses primarily on pediatric nephrotic syndrome, adult management follows similar principles with supportive care (sodium restriction, diuretics, ACE inhibitors/ARBs, statins) being universally applicable 3. However, the underlying histologic subtypes differ, with membranous nephropathy and focal segmental glomerulosclerosis being more common in adults 3.

Secondary Causes

Before initiating immunosuppressive therapy, rule out secondary causes including diabetes mellitus, systemic lupus erythematosus, medications, infections, and malignancies 5, 3. This is essential as treatment strategies differ significantly for secondary nephrotic syndrome.

Monitoring Strategy

Inpatient monitoring is required for patients with:

  • Significant edema
  • Severe hypertension (stage 2)
  • Acute kidney injury 6

Long-term follow-up should include:

  • Urinalysis for proteinuria monitoring (home monitoring can be taught to families)
  • Serum creatinine
  • Blood pressure monitoring
  • Assessment for medication adverse effects 7

References

Research

Improved outcomes in nephrotic syndrome.

Cleveland Clinic journal of medicine, 2006

Research

Diagnosis and Management of Nephrotic Syndrome in Adults.

American family physician, 2016

Research

[Nephrotic syndrome].

Innere Medizin (Heidelberg, Germany), 2025

Research

Nephrotic Syndrome: Current Management.

Indian journal of pediatrics, 2026

Related Questions

What is the recommended treatment plan for a patient presenting with nephrotic‑nephritic syndrome (edema, proteinuria, hypoalbuminemia) while awaiting renal biopsy?
What are the diagnostic criteria for nephritic syndrome?
What is the appropriate management for a patient with nephrotic syndrome and chronic kidney disease?
What is the appropriate evaluation and management of papilledema in a patient with nephrotic syndrome?
What is the clinical significance of a past history of nephrotic syndrome?
Can you interpret the arterial blood gas results (arterial pH 7.46, arterial partial pressure of carbon dioxide 41 mmHg, arterial partial pressure of oxygen 83 mmHg, arterial oxygen saturation 98%, arterial bicarbonate 29.4 mmol/L, base excess +5.6, hemoglobin 9.6 g/dL) obtained from the left radial artery on an inspired oxygen fraction of 32% with a positive Allen test?
Can Spiriva Respimat (tiotropium bromide) be used with an AeroChamber spacer?
Were metformin, sulfonylureas, and thiazolidinediones the most extensively studied oral antidiabetic agents before 2020, and during which period was research on these drugs at its peak?
Which juices are suitable and beneficial for a breastfeeding mother?
What is the recommended intravenous fosfomycin dosage for adult patients with pneumonia, including adjustments for varying renal function?
What coagulation parameters (platelet count, international normalized ratio, prothrombin time, activated partial thromboplastin time) are considered safe for women undergoing minor surgical procedures?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.